# Imeroprubart PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/imeroprubart

> The next catalyst for imeroprubart, sponsored by Immunovant, Inc. (IMVT), is its topline data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, year only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for imeroprubart?

The next catalyst for imeroprubart, sponsored by Immunovant, Inc. (IMVT), is its topline data readout, 2027. Press release filed with the SEC (EX-99): "The Company expects to report topline data across potentially registrational trials of IMVT-1402 in Graves' disease (GD) and myasthenia gravis (MG) in calendar year 2027." [Calendar and source filings](https://sec-api.dev/pdufa/imeroprubart)

Source: Press release filed with the SEC (EX-99), accession 0001764013-26-000121, https://www.sec.gov/Archives/edgar/data/1764013/000176401326000121/exhibit9912026119.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/pdufa/imeroprubart#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | imeroprubart |
| Codes | IMVT-1402 |
| Sponsor | Immunovant, Inc. (IMVT) https://sec-api.dev/companies/imvt/catalysts |
| Indications | [graves' disease](https://sec-api.dev/indications/graves-disease), anti-citrullinated protein autoantibody, active, anti-citrullinated protein autoantibody, [Chronic Inflammatory Demyelinating Polyneuropathy](https://sec-api.dev/indications/chronic-inflammatory-demyelinating-polyneuropathy) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### June 30, 2023: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2025-02-06, last confirmed 2025-02-06.
- SEC Form 10-Q (accession 0001764013-25-000026): "In the quarter ended June 30, 2023, the FDA cleared our IND application for IMVT-1402 and we initiated a Phase 1 clinical trial in healthy adults in New Zealand after approval of the Clinical Trial Application ("CTA") by the regulatory authority, MEDSAFE." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000026/imvt-20241231.htm

### Dec 2024: trial start

- Status: completed. Date confidence: month. Indication: anti-citrullinated protein autoantibody.
- First seen 2025-12-11, last confirmed 2026-11-09.
- SEC Form 8-K (accession 0001193125-25-314994): "Immunovant, Inc. ("we") initiated a potentially registrational trial evaluating IMVT-1402 in anti-citrullinated protein autoantibody ("ACPA") positive D2T RA in December 2024." https://www.sec.gov/Archives/edgar/data/1764013/000119312525314994/d760155d8k.htm
- SEC Form 10-Q (accession 0001764013-26-000122): "In December 2024 and June 2025, we initiated two potentially registrational trials (NCT06727604 and NCT07018323, respectively) evaluating IMVT-1402 in adults with GD." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000122/imvt-20260930.htm
- SEC Form 10-Q (accession 0001764013-26-000122): "In December 2024, we initiated a potentially registrational, multicenter, randomized withdrawal trial (NCT06754462) evaluating IMVT-1402 in adults with anti-citrullinated protein autoantibody ("ACPA") positive D2T RA who have had an inadequate response to two or more prior mechanisms of advanced therapy, including biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs)." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000122/imvt-20260930.htm
- SEC Form 10-Q (accession 0001764013-26-000101): "In December 2024 and June 2025, we initiated two potentially registrational trials (NCT06727604 and NCT07018323, respectively) evaluating IMVT-1402 in adults with GD." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000101/imvt-20260630.htm
- SEC Form 10-Q (accession 0001764013-26-000101): "In December 2024, we initiated a potentially registrational trial (NCT06754462) evaluating IMVT-1402 in anti-citrullinated protein autoantibody ("ACPA") positive D2T RA." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000101/imvt-20260630.htm
- SEC Form 10-K (accession 0001764013-26-000064): "In December 2024, we initiated a potentially registrational trial evaluating IMVT-1402 in adults with GD." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- SEC Form 10-K (accession 0001764013-26-000064): "In December 2024, we initiated a potentially registrational trial evaluating IMVT-1402 in ACPA-positive D2T RA." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- SEC Form 10-K (accession 0001764013-26-000064): "In December 2024 and June 2025, we initiated two potentially registrational trials (NCT06727604 and NCT07018323, respectively) evaluating IMVT-1402 in adults with GD." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- SEC Form 10-K (accession 0001764013-26-000064): "In December 2024, we initiated a potentially registrational trial (NCT06754462) evaluating IMVT-1402 in anti-citrullinated protein autoantibody ("ACPA") positive D2T RA." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm

### 2025: trial start

- Status: scheduled. Date confidence: year.
- First seen 2025-05-29, last confirmed 2025-05-29.
- SEC Form 10-K (accession 0001140361-25-020715): "We also plan to initiate a potentially registrational trial evaluating IMVT-1402 in Sjögren's disease and a second potentially registrational trial in GD in the summer of calendar year 2025." https://www.sec.gov/Archives/edgar/data/1635088/000114036125020715/ef20047582_10k.htm

### March 31, 2025: trial start

- Status: completed. Date confidence: exact. Indication: active, anti-citrullinated protein autoantibody.
- First seen 2024-11-12, last confirmed 2026-11-09.
- SEC Form 10-Q (accession 0001764013-25-000026): "For example, we expect our research and development expenses to significantly increase as we seek to execute our plan to initiate four to five potentially registrational programs for IMVT-1402 by March 31, 2025 and initiate trials of IMVT-1402 in ten indications (inclusive of the four to five programs initiated in fiscal 2025) by March 31, 2026." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000026/imvt-20241231.htm
- SEC Form 10-Q (accession 0001764013-25-000026): "For example, we will require substantial capital to execute our plan to initiate four to five potentially registrational programs for IMVT-1402 by March 31, 2025 and initiate trials of IMVT-1402 in ten indications (inclusive of the four to five programs initiated in fiscal 2025) by March 31, 2026." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000026/imvt-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-25-000091): "In March 2025, Immunovant initiated a potentially registrational trial of IMVT-1402 in adult participants with active, anti-citrullinated protein autoantibody (ACPA) positive D2T RA and a proof-of-concept study in CLE." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000091/exhibit9912025529.htm
- SEC Form 10-Q (accession 0001764013-26-000122): "In March 2025, we initiated a potentially registrational trial (NCT07039916) evaluating IMVT-1402 in adults with MG." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000122/imvt-20260930.htm
- SEC Form 10-Q (accession 0001764013-26-000122): "In March 2025, we initiated a potentially registrational trial (NCT07032662) evaluating IMVT-1402 in adults with CIDP." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000122/imvt-20260930.htm
- SEC Form 10-Q (accession 0001764013-26-000101): "In March 2025, we initiated a potentially registrational trial (NCT07039916) evaluating IMVT-1402 in adults with MG." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000101/imvt-20260630.htm
- SEC Form 10-Q (accession 0001764013-26-000101): "In March 2025, we initiated a potentially registrational trial (NCT07032662) evaluating IMVT-1402 in adults with CIDP." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000101/imvt-20260630.htm
- SEC Form 10-K (accession 0001764013-26-000064): "In March 2025, we initiated a potentially registrational trial evaluating IMVT-1402 in adults with MG." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- SEC Form 10-K (accession 0001764013-26-000064): "In March 2025, we initiated a potentially registrational trial evaluating IMVT-1402 in adults with CIDP." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- SEC Form 10-K (accession 0001764013-26-000064): "In March 2025, we initiated a potentially registrational trial (NCT07039916) evaluating IMVT-1402 in adults with MG." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- SEC Form 10-K (accession 0001764013-26-000064): "In March 2025, we initiated a potentially registrational trial (NCT07032662) evaluating IMVT-1402 in adults with CIDP." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0001846253-24-000086): "The company also announced that it is on track to initiate potentially registrational trials with IMVT-1402 in four to five indications, including Graves' disease (GD) and D2T RA, by March 31, 2025." https://www.sec.gov/Archives/edgar/data/1846253/000184625324000086/a2024q3ex991.htm

### Jun 2025: trial start

- Status: completed. Date confidence: month.
- First seen 2025-08-11, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001764013-25-000128): "•Initiated a second potentially registrational study of IMVT-1402 in Graves' disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren's disease (SjD), both in June 2025" https://www.sec.gov/Archives/edgar/data/1764013/000176401325000128/exhibit9912025811.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-25-000128): "In June 2025, Immunovant initiated a second potentially registrational trial evaluating IMVT-1402 in GD and a potentially registrational trial evaluating IMVT-1402 in SjD." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000128/exhibit9912025811.htm
- SEC Form 10-Q (accession 0001764013-26-000122): "In June 2025, we initiated a potentially registrational trial (NCT06979531) evaluating IMVT-1402 in SjD." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000122/imvt-20260930.htm
- SEC Form 10-Q (accession 0001764013-26-000101): "In June 2025, we initiated a potentially registrational trial (NCT06979531) evaluating IMVT-1402 in SjD." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000101/imvt-20260630.htm
- SEC Form 10-K (accession 0001764013-26-000064): "In June 2025, we initiated a second potentially registrational trial evaluating IMVT-1402 in adults with GD." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- SEC Form 10-K (accession 0001764013-26-000064): "In June 2025, we initiated a potentially registrational trial evaluating IMVT-1402 in SjD." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- SEC Form 10-K (accession 0001764013-26-000064): "In June 2025, we initiated a potentially registrational trial (NCT06979531) evaluating IMVT-1402 in SjD." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm

### 2H 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-01-14, last confirmed 2025-01-14.
- Press release filed with the SEC (EX-99) (accession 0001764013-25-000009): "Multiple near-term milestones for enhanced value creation Jan 2025 TED: Topline results for both trials expected in 2H 2025 MG: Topline Phase 3 results, and CIDP: Initial Phase 2b period 1 data expected by March 31, 20252 1." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000009/exhibit991.htm

### 2H 2026: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-05-29, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001764013-26-000100): "The Company expects to provide further updates on its potentially registrational IMVT-1402 D2T RA program and report topline data from the proof-of-concept trial of IMVT-1402 in CLE in the second half of calendar year 2026." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/exhibit991202686.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-26-000010): "•IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of calendar year 2026" https://www.sec.gov/Archives/edgar/data/1764013/000176401326000010/exhibit991202626.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-26-000010): "The Company's potentially registrational trial evaluating IMVT-1402 in D2T RA is fully enrolled, with topline data expected in the second half of calendar year 2026." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000010/exhibit991202626.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-25-000148): "Immunovant expects to report results from the open-label portion of the potentially registrational trial of IMVT-1402 in D2T RA and topline results from the proof-of-concept trial of IMVT-1402 in CLE in calendar year 2026." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000148/exhibit99120251110.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-25-000128): "In the calendar year 2026, the company expects to report results from the open-label portion of the potentially registrational trial of IMVT-1402 in D2T RA and top-line results from the proof-of-concept trial of IMVT-1402 in CLE." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000128/exhibit9912025811.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-26-000062): "•IMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus (CLE) fully enrolled with topline data expected in the second half of calendar year 2026" https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/exhibit9912026520.htm
- SEC Form 8-K (accession 0001193125-25-314994): "We now also expect to report top line results from this trial in 2026." https://www.sec.gov/Archives/edgar/data/1764013/000119312525314994/d760155d8k.htm
- SEC Form 10-Q (accession 0001764013-26-000101): "The trial is fully enrolled and we expect to report top-line results from this trial in the second half of calendar year 2026." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000101/imvt-20260630.htm
- SEC Form 10-K (accession 0001764013-26-000064): "We expect to report top-line results from this trial in the second half of calendar year 2026." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- SEC Form 10-Q (accession 0001764013-26-000011): "The trial is fully enrolled, and we now expect to report top-line results from this trial in the second half of calendar year 2026." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000011/imvt-20251231.htm
- SEC Form 10-Q (accession 0001764013-26-000011): "We expect to report top-line results from this trial in the second half of calendar year 2026." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000011/imvt-20251231.htm
- SEC Form 10-Q (accession 0001764013-25-000149): "We expect to report top-line results from this trial in 2026." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000149/imvt-20250930.htm

### 2027: topline data readout

- Status: scheduled. Date confidence: year. Indication: Graves' Disease.
- First seen 2025-05-29, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001764013-26-000121): "The Company expects to report topline data across potentially registrational trials of IMVT-1402 in Graves' disease (GD) and myasthenia gravis (MG) in calendar year 2027." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000121/exhibit9912026119.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-26-000100): "In calendar year 2027, topline data are anticipated for the potentially registrational trials evaluating IMVT-1402 in GD and MG." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/exhibit991202686.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-26-000062): "In calendar year 2027, topline data are expected across potentially registrational trials of IMVT-1402 in GD and MG." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/exhibit9912026520.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-26-000010): "In calendar year 2027, topline data are expected across potentially registrational trials of IMVT-1402 in each of GD and MG." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000010/exhibit991202626.htm
- SEC Form 8-K (accession 0001193125-25-314994): "Other than the D2T RA update above, we continue to expect to meet our previously disclosed anticipated milestones, including for the two potentially registrational trials evaluating IMVT-1402 in adults with Graves' Disease, for which we expect to report top-line results in 2027." https://www.sec.gov/Archives/edgar/data/1764013/000119312525314994/d760155d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-25-000148): "In calendar year 2027, topline results are expected across three indications from the potentially registrational trials of IMVT-1402 in GD, MG and D2T RA." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000148/exhibit99120251110.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-25-000136): "•Two potentially registrational trials for IMVT-1402 in Graves' disease are currently enrolling with topline readouts expected in 2027" https://www.sec.gov/Archives/edgar/data/1764013/000176401325000136/exhibit991202593.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-25-000136): "The two potentially registrational global trials for IMVT-1402 in Graves' disease are currently enrolling with topline readouts expected in 2027." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000136/exhibit991202593.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-25-000128): "In the calendar year 2027, top-line results are expected across three indications from the potentially registrational trials of IMVT-1402 in D2T RA, GD and MG." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000128/exhibit9912025811.htm
- SEC prospectus (424B) (accession 0001193125-25-316765): "D2T RA update above, we continue to expect to meet our previously disclosed anticipated milestones, including for the two potentially registrational trials evaluating IMVT-1402 in adults with Graves' Disease, for which we expect to report top-line results in 2027." https://www.sec.gov/Archives/edgar/data/1764013/000119312525316765/d47651d424b5.htm
- SEC Form 8-K (accession 0001193125-25-314994): "Except for D2T RA, the first top-line data for any of the potentially registrational studies is not expected until sometime in calendar year 2027, assuming we can fully enroll and successfully complete the relevant trials according to our anticipated timelines." https://www.sec.gov/Archives/edgar/data/1764013/000119312525314994/d760155d8k.htm
- SEC Form 10-K (accession 0001764013-25-000092): "The first top-line data for any of the potentially registrational studies is not expected until sometime in calendar year 2027, assuming we can fully enroll and successfully complete the relevant trials according to our anticipated timelines." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000092/imvt-20250331.htm

### August 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Chronic Inflammatory Demyelinating Polyneuropathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07032662 (Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." https://clinicaltrials.gov/study/NCT07032662

### Aug to Nov 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Chronic Inflammatory Demyelinating Polyneuropathy.
- First seen 2025-05-29, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07032662 (Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." https://clinicaltrials.gov/study/NCT07032662
- Press release filed with the SEC (EX-99) (accession 0001764013-26-000121): "In calendar year 2028, topline data are expected for the potentially registrational trial of IMVT-1402 in chronic inflammatory demyelinating polyneuropathy (CIDP)." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000121/exhibit9912026119.htm
- Press release filed with the SEC (EX-99) (accession 0001764013-26-000100): "Topline data are expected to follow in calendar year 2028 for the potentially registrational trials of IMVT-1402 in CIDP and SjD." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/exhibit991202686.htm
- SEC Form 10-Q (accession 0001764013-26-000122): "We expect to report top-line results from this trial in calendar year 2028." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000122/imvt-20260930.htm
- SEC Form 10-Q (accession 0001764013-26-000101): "We expect to report top-line results from this trial in calendar year 2028." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000101/imvt-20260630.htm
- SEC Form 10-K (accession 0001764013-26-000064): "We expect to report top-line results from this trial in calendar year 2028." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- SEC Form 10-Q (accession 0001764013-26-000011): "We expect to report top-line results from this trial in 2028." https://www.sec.gov/Archives/edgar/data/1764013/000176401326000011/imvt-20251231.htm
- SEC Form 10-Q (accession 0001764013-25-000149): "We expect to report top-line results from this trial in 2028." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000149/imvt-20250930.htm
- SEC Form 10-Q (accession 0001764013-25-000129): "We expect to report top-line results from this trial in 2028." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000129/imvt-20250630.htm
- SEC Form 10-K (accession 0001764013-25-000092): "We expect to report top-line results from this trial in 2028." https://www.sec.gov/Archives/edgar/data/1764013/000176401325000092/imvt-20250331.htm
- Press release filed with the SEC (EX-99) (accession 0001635088-26-000130): "In calendar year 2028, topline data are expected for the potentially registrational trial of IMVT-1402 in CIDP." https://www.sec.gov/Archives/edgar/data/1635088/000163508826000130/q2fy2026roivantearningsrel.htm
- Press release filed with the SEC (EX-99) (accession 0001635088-26-000088): "In calendar year 2028, topline data are expected across potentially registrational trials of IMVT-1402 in CIDP and SjD." https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm

## Same indication

- [Batoclimab](https://sec-api.dev/pdufa/batoclimab) (IMVT)
- [Batoclimab 680 milligrams (mg) subcutaneous (sc) weekly](https://sec-api.dev/pdufa/batoclimab-680-milligrams-mg-subcutaneous-sc-weekly) (IMVT)
- [MoDE (BHV-1300)](https://sec-api.dev/pdufa/bhv-1300) (BHVN)
- [Claseprubart](https://sec-api.dev/pdufa/claseprubart) (DNTH)
- [Empasiprubart](https://sec-api.dev/pdufa/empasiprubart) (ARGX)
- [Empasiprubart iv](https://sec-api.dev/pdufa/empasiprubart-iv) (ARGX)
- [LCA-0321](https://sec-api.dev/pdufa/lca-0321) (LYCA)
- [Riliprubart](https://sec-api.dev/pdufa/riliprubart) (SNY)
- [VRDN-292](https://sec-api.dev/pdufa/vrdn-292) (VRDN)
- [YB-101](https://sec-api.dev/pdufa/yb-101) (YARW)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/imeroprubart.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Imeroprubart PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/imeroprubart

```bibtex
@misc{secapidev_pdufa_imeroprubart_20261116,
  title        = {Imeroprubart PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/imeroprubart}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_imeroprubart_20261116","title":"Imeroprubart PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/imeroprubart","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
